Testicular Cancer Treatment and Survival Rates Are Improving

August 25, 2021 by Elisa Becze BA, ELS, Editor

Progression-free and overall survival rates for patients with metastatic testicular cancer have significantly grown since 1990, researchers reported (https://ascopubs.org/doi/10.1200/JCO.20.03292) in the Journal of Clinical Oncology.

The researchers compared data on 2,451 patients with metastatic seminoma who received cisplatin- and etoposide-based first-line chemotherapy from 1990–2013. During that timeframe, five-year progression-free survival rates improved from 82% to 89% and five-year overall survival rates grew from 86% to 95% in patients with a good prognosis and from 67%–79% to 72%–88% in those with an intermediate prognosis.

The researchers also used the study to identify a new adverse prognostic factor: lactate dehydrogenase (LDH). They found that both progression-free and overall survival in patients with good prognosis who had an LDH higher than 2.5 x upper limit of normal were similar to patients with an intermediate prognosis. They proposed adding LDH as an adverse prognostic factor to the International Germ-Cell Cancer Collaborative Group classification for patients with an otherwise good prognosis.

“Given five-year progression-free and overall survival probabilities of 88% and 95%, respectively, across all prognostic groups, metastatic seminoma represents the most curable metastatic cancer in assigned males,” the researchers said (https://ascopubs.org/doi/10.1200/JCO.20.03292).

Find tools and resources for oncology nursing survivorship care in ONS’s Survivorship Learning Library (https://www.ons.org/learning-libraries/survivorship).


Copyright © 2021 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact pubpermissions@ons.org for quantity reprints or permission to adapt, excerpt, post online, or reuse ONS Voice content for any other purpose.